NASDAQ:AUTL

Autolus Therapeutics Stock Forecast, Price & News

$6.61
+0.07 (+1.07 %)
(As of 09/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.44
$6.72
50-Day Range
$5.32
$7.37
52-Week Range
$4.60
$13.29
Volume265,495 shs
Average Volume1.21 million shs
Market Capitalization$480.83 million
P/E RatioN/A
Dividend YieldN/A
Beta1.72
30 days | 90 days | 365 days | Advanced Chart
Receive AUTL News and Ratings via Email

Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Autolus Therapeutics logo

About Autolus Therapeutics

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.68 out of 5 stars

Medical Sector

934th out of 1,352 stocks

Biological Products, Except Diagnostic Industry

146th out of 193 stocks

Analyst Opinion: 3.4Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Autolus Therapeutics (NASDAQ:AUTL) Frequently Asked Questions

Is Autolus Therapeutics a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Autolus Therapeutics stock.
View analyst ratings for Autolus Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Autolus Therapeutics?

Wall Street analysts have given Autolus Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Autolus Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Autolus Therapeutics?

Autolus Therapeutics saw a increase in short interest in August. As of August 13th, there was short interest totaling 2,810,000 shares, an increase of 30.1% from the July 29th total of 2,160,000 shares. Based on an average daily trading volume, of 1,780,000 shares, the days-to-cover ratio is currently 1.6 days.
View Autolus Therapeutics' Short Interest
.

When is Autolus Therapeutics' next earnings date?

Autolus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Autolus Therapeutics
.

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics plc (NASDAQ:AUTL) announced its quarterly earnings results on Thursday, August, 5th. The company reported ($0.47) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.50) by $0.03. The business had revenue of $1.65 million for the quarter, compared to analyst estimates of $0.31 million. Autolus Therapeutics had a negative trailing twelve-month return on equity of 56.93% and a negative net margin of 4,890.43%.
View Autolus Therapeutics' earnings history
.

How has Autolus Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Autolus Therapeutics' stock was trading at $6.77 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AUTL shares have decreased by 2.4% and is now trading at $6.61.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for AUTL?

7 equities research analysts have issued twelve-month target prices for Autolus Therapeutics' shares. Their forecasts range from $9.00 to $21.00. On average, they expect Autolus Therapeutics' share price to reach $14.67 in the next year. This suggests a possible upside of 121.9% from the stock's current price.
View analysts' price targets for Autolus Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Autolus Therapeutics' key executives?

Autolus Therapeutics' management team includes the following people:
  • Christian Martin Itin, Chief Executive Officer & Director
  • Christopher Vann, Chief Operating Officer & Senior Vice President
  • Andrew J. Oakley, Chief Financial Officer & Senior Vice President
  • Martin Pulé, Chief Scientific Officer & Senior Vice President
  • David Brochu, Chief Technical Officer & Senior Vice President

Who are some of Autolus Therapeutics' key competitors?

What other stocks do shareholders of Autolus Therapeutics own?

When did Autolus Therapeutics IPO?

(AUTL) raised $125 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

What is Autolus Therapeutics' stock symbol?

Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."

Who are Autolus Therapeutics' major shareholders?

Autolus Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Citadel Advisors LLC (3.92%), Polygon Management Ltd. (3.55%), Frazier Management LLC (3.24%), Nantahala Capital Management LLC (2.54%), Ikarian Capital LLC (1.86%) and JPMorgan Chase & Co. (1.06%).

Which institutional investors are selling Autolus Therapeutics stock?

AUTL stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC, New York State Common Retirement Fund, and Cubist Systematic Strategies LLC.

Which institutional investors are buying Autolus Therapeutics stock?

AUTL stock was acquired by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Frazier Management LLC, Nantahala Capital Management LLC, Goldman Sachs Group Inc., Millennium Management LLC, Marshall Wace LLP, Marshall Wace LLP, and JPMorgan Chase & Co..

How do I buy shares of Autolus Therapeutics?

Shares of AUTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Autolus Therapeutics' stock price today?

One share of AUTL stock can currently be purchased for approximately $6.61.

How much money does Autolus Therapeutics make?

Autolus Therapeutics has a market capitalization of $480.83 million and generates $1.72 million in revenue each year. The company earns $-142,090,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis.

How many employees does Autolus Therapeutics have?

Autolus Therapeutics employs 376 workers across the globe.

What is Autolus Therapeutics' official website?

The official website for Autolus Therapeutics is www.autolus.com.

Where are Autolus Therapeutics' headquarters?

Autolus Therapeutics is headquartered at FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ.

How can I contact Autolus Therapeutics?

Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company can be reached via phone at 442038296230 or via email at [email protected].


This page was last updated on 9/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.